Positrigo will be presenting NeuroLF at the conference of the European Association of Nuclear Medicine (EANM), which is set to take place September 9-13 in Vienna, further details of which can be found in a LinkedIn post. The Zurich-based firm developed its positron emission tomography (PET) system for the brain to facilitate the diagnosis and monitoring of brain diseases such as Alzheimer’s, Parkinson’s and epilepsy, as well as tumors.
According to information from the company itself, NeuroLF is characterized by its minimalist design and value for money, with the device also described as being ultra-compact and patient-centric. In the press release, Positrigo quoted comments made in June by Professor Osama Sabri and Professor Bernhard Sattler from the Nuclear Medicine Clinic in Leipzig, Germany, during the presentation of preliminary performance data: “The first data show that NeuroLF produces similar images compared to a conventional digital PET/CT and is not inferior in comparison to such more expensive devices”.
Positrigo was founded in 2018 at the Institute for Particle Physics and Astrophysics of the Swiss Federal Institute of Technology in Zurich (ETH). The company is headquartered at Technopark Zurich. You can book online for the presentation of NeuroLF at the EANM conference.
